Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306

被引：0
|
作者：
Raymond, E. [1 ]
Xu, J. [2 ]
Kato, K. [3 ]
Hubner, R. [4 ]
Shu, Y. [5 ]
Park, S. R. [6 ]
Kojima, T. [7 ]
Wyrwicz, L. S. [8 ]
Tougeron, D. [9 ]
Geboes, K. [10 ]
Van Cutsem, E. [11 ,12 ]
Pazo Cid, R. A. [13 ]
Zaanan, A. [14 ]
McLachlan, S-A. [15 ]
Wu, H. [16 ]
Shi, J. [17 ]
Li, L. [18 ]
Yan, S. [19 ]
Yoon, H. [20 ]
机构：
[1] Hop St Louis, AP HP, Clin Dev, Paris, France
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Gastrointestinal Dept, Beijing 302 Hosp, Beijing, Peoples R China
[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan
[4] Christie NHS Fdn Trust, Clin Dev, Manchester, Lancs, England
[5] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[6] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
[9] CHU Poitiers Jean Bernard Hop, Clin Dev, Poitiers, France
[10] UZ Gent Univ Hosp Ghent, Gastroenterol Dept, Ghent, Belgium
[11] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium
[12] Univ Leuven KU Leuven, Gastroenterol Digest Oncol, Leuven, Belgium
[13] Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain
[14] Hop Europeen Georges Pompidou, AP HP, Hepatogastroenterol & Digest Oncol, Paris, France
[15] GenesisCare St Vincents Hosp, Clin Dev, Melbourne, Vic, Australia
[16] BeiGene USA Inc, Stat & Data Sci, Ridgefield, NJ USA
[17] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Biomarker, Beijing, Peoples R China
[18] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Dev, Beijing, Peoples R China
[19] BeiGene Beijing Co Ltd, Clin Dev, Beijing, Peoples R China
[20] Mayo Clin, Dept Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
395MO
引用
收藏
页码：S159 / S159
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Qian, Ting
    Liu, Delin
    Cao, Guochun
    Chen, Zhipeng
    Zhang, Qin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [22] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, H-T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A. V.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1527
  • [23] Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma
    Yoon, Harry H.
    Kato, Ken
    Hubner, Richard
    Raymond, Eric
    Tao, Aiyang
    Liu, Sumei
    Qazi, Ibrahim
    Xu, Jian-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
    Xu, R-H.
    Oh, D-Y.
    Kato, K.
    Arkenau, T.
    Tabernero, J.
    Cruz-Correa, M.
    Zimina, A.
    Bai, Y.
    Shi, J.
    Lee, K-W.
    Hirano, H.
    Spigel, D. R.
    Wyrwicz, L. S.
    Cid, R. A. Pazo
    Li, L.
    Xu, Y.
    McHenry, M. B.
    Yang, S.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1320 - S1321
  • [25] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [26] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [27] Cost-effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
    Zhang, Li
    Su, Henghai
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
    Li, Y.
    Zhou, A.
    Liu, S.
    He, M.
    Chen, K-N.
    Tian, Z.
    Chen, H.
    Tian, H.
    Yu, Y.
    Qu, W.
    Xue, L.
    Wang, S.
    Bie, F.
    Zhou, B.
    Huang, H. Y.
    Fang, Y.
    Li, B.
    Dai, X.
    Gao, S.
    He, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1101 - S1101
  • [29] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
    Xu, Rui-hua
    Kim, Sung-Bae
    Tougeron, David
    Zuo, Yunxia
    Yang, Haiyuan
    Zhang, Juan
    Shi, Jingwen
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
    You, Maojin
    Huang, Yufan
    Cai, Zhongjie
    Wu, Qingfeng
    Zhu, Wei
    He, Ying
    Chen, Ruijia
    FRONTIERS IN ONCOLOGY, 2022, 12
12345